CTGF inhibits cell motility and COX-2 expression in oral cancer cells

Int Immunopharmacol. 2011 Aug;11(8):948-54. doi: 10.1016/j.intimp.2011.02.008. Epub 2011 Feb 23.

Abstract

Oral squamous cell carcinoma (SCC) has a striking tendency to migrate and metastasize. Cyclooxygenase (COX)-2, the inducible isoform of prostaglandin synthase, has been implicated in tumor metastasis. Connective tissue growth factor (CTGF), a secreted protein that binds to integrins, modulates the invasive behavior of certain human cancer cells. However, the effect of CTGF on migration activity and COX-2 expression in human oral cells is mostly unknown. Here we found that CTGF reduced the migration and expression of COX-2 in human oral cancer cells. αvβ5 monoclonal antibody (mAb), phosphatidylinositol 3-kinase inhibitor (PI3K; Ly294002 and wortmannin) and Akt inhibitor reversed the CTGF-inhibited the migration and COX-2 down-regulation of oral cancer cells. CTGF stimulation decreased the phosphorylation of focal adhesion kinase (FAK), PI3K and Akt. In addition, c-Jun siRNA also antagonized the CTGF-inhibited migration and COX-2 expression. Moreover, CTGF decreased the binding of c-Jun to the AP-1 element on the COX-2 promoter. Taken together, our results indicated that CTGF inhibits the migration of oral cancer cells by decreasing COX-2 expression through the αvβ5 integrin receptor, FAK, PI3K, Akt, c-Jun and AP-1 signal transduction pathways.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androstadienes / pharmacology
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Cell Line, Tumor
  • Cell Movement / drug effects*
  • Chromones / pharmacology
  • Connective Tissue Growth Factor / antagonists & inhibitors
  • Connective Tissue Growth Factor / metabolism
  • Connective Tissue Growth Factor / pharmacology*
  • Cyclooxygenase 2 / biosynthesis*
  • Cyclooxygenase 2 / genetics
  • Down-Regulation
  • Focal Adhesion Kinase 1 / metabolism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Genes, jun / genetics
  • Humans
  • Morpholines / pharmacology
  • Mouth Neoplasms / drug therapy
  • Mouth Neoplasms / genetics
  • Mouth Neoplasms / metabolism*
  • Mouth Neoplasms / pathology*
  • Phosphatidylinositol 3-Kinase / metabolism
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation / drug effects
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / metabolism
  • RNA, Small Interfering / administration & dosage
  • RNA, Small Interfering / genetics
  • Receptors, Vitronectin / immunology
  • Signal Transduction / drug effects
  • Transcription Factor AP-1 / metabolism
  • Wortmannin

Substances

  • Androstadienes
  • Antibodies, Monoclonal
  • CCN2 protein, human
  • Chromones
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • RNA, Small Interfering
  • Receptors, Vitronectin
  • Transcription Factor AP-1
  • integrin alphaVbeta5
  • Connective Tissue Growth Factor
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Phosphatidylinositol 3-Kinase
  • Focal Adhesion Kinase 1
  • PTK2 protein, human
  • Proto-Oncogene Proteins c-akt
  • Wortmannin